AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 9.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,136 shares of the company’s stock after buying an additional 543 shares during the period. Wealthcare Advisory Partners LLC’s holdings in AstraZeneca were worth $416,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of AZN. Brookstone Capital Management purchased a new stake in shares of AstraZeneca during the 1st quarter worth approximately $315,000. Gilman Hill Asset Management LLC acquired a new position in AstraZeneca in the first quarter valued at $251,000. Harbor Investment Advisory LLC grew its holdings in shares of AstraZeneca by 81.3% during the first quarter. Harbor Investment Advisory LLC now owns 1,434 shares of the company’s stock worth $97,000 after purchasing an additional 643 shares during the last quarter. Global Assets Advisory LLC acquired a new stake in shares of AstraZeneca during the first quarter worth about $2,734,000. Finally, AdvisorNet Financial Inc lifted its holdings in shares of AstraZeneca by 10.7% in the 1st quarter. AdvisorNet Financial Inc now owns 21,973 shares of the company’s stock valued at $1,489,000 after purchasing an additional 2,120 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Down 0.2 %

Shares of NASDAQ:AZN opened at $77.99 on Monday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The firm’s 50-day simple moving average is $77.52 and its 200-day simple moving average is $70.43. The company has a market cap of $241.81 billion, a price-to-earnings ratio of 38.23, a PEG ratio of 1.40 and a beta of 0.48.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. As a group, equities research analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of several research analyst reports. Argus lifted their price target on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. BMO Capital Markets lifted their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. The Goldman Sachs Group began coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.